Urogenital atrophy is a chronic condition in which the tissue quality of the vulva, vagina, urethra, and bladder become progressively affected, usually in postmenopausal women. The condition results from estrogen deficiency, though symptoms may not become apparent for several years after menopause. It has been described as a “silent epidemic”, with a lack of awareness detrimentally affecting rates of diagnosis and access to treatment. Indeed, symptoms are thought to exert a negative impact on the quality of life of up to 50% of postmenopausal women.

This short course has been designed to teach healthcare providers everything they need to know about urogenital atrophy in order to increase recognition and improve patient care. It should take approximately 30 minutes to complete.

This course has a 2-year expiry date of 3rd November 2025. If you complete this course after its expiry date, please double check all claims in this course with up-to-date, peer-reviewed information, as the diagnostic or treatment landscape may have changed.

CME/CPD Information

This course has been accredited by the European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) with 1 European CME credit (ECMEC®).

This accreditation certifies the quality and relevance of the educational content.

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™.

This course is also accredited by the Royal College of General Practitioners for the period of 12th September 2024 to 11th September 2025.